Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
March 18, 2024 08:00 ET
|
Biora Therapeutics, Inc.
Biora's management will host a webcast and conference call on Tuesday, March 26, 2024, after the close of financial markets.
Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset
March 11, 2024 08:00 ET
|
Biora Therapeutics, Inc.
Monetization of legacy asset brings in $3 million in nondilutive capital; note exchange brings in another $2.8 million in capital, reduces net debt
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
February 26, 2024 08:00 ET
|
Biora Therapeutics, Inc.
Data from SAD cohort expected to be shared during March corporate update; MAD cohorts to begin dosing in March.
Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium
February 08, 2024 08:00 ET
|
Biora Therapeutics, Inc.
Dr. Ariella Kelman to participate in panel titled "The Next Evolutionary Steps in Addressing IBD" on Feb 28, 2024.
Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.
January 22, 2024 08:00 ET
|
Biora Therapeutics, Inc.
Biora will participate in a virtual fireside chat hosted by H.C. Wainwright & Co. on Monday, January 29, 2024 at 11:00 AM Eastern / 8:00 AM Pacific.
Biora Therapeutics Provides Outlook for 2024
January 16, 2024 08:00 ET
|
Biora Therapeutics, Inc.
Biora anticipates 2024 catalysts, including clinical study results for NaviCap™ platform and progress on pharma partnerships for BioJet™ platform.
Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600
January 08, 2024 08:00 ET
|
Biora Therapeutics, Inc.
SAD/MAD study to evaluate safety and PK/PD of BT-600 drug-device combination, including concentrations in colon tissue
Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
January 02, 2024 08:00 ET
|
Biora Therapeutics, Inc.
Biora's BioJet™ drug delivery platform exceeded performance targets for delivery of collaborator AstraZeneca’s molecule in preclinical study.
Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform
December 19, 2023 08:00 ET
|
Biora Therapeutics, Inc.
Biora's latest patent addresses targeted delivery of JAK inhibitors to the gastrointestinal tract.
Biora Therapeutics Accelerates Debt Reduction and Raises Capital with Large Institutional Investors
December 18, 2023 08:00 ET
|
Biora Therapeutics, Inc.
Transaction results in nearly 60% reduction in net debt and brings $16 million in new capital; demonstrates investor confidence in near-term catalysts.